

3. (Amended) A method of treatment of melanoma, breast, colon, ovarian, renal, central nervous system, bladder, prostate or lung cancer in a human in need of such treatment, which comprises administering a therapeutically effective amount of one or more arsenic compounds to said human.

9. (Amended) The method of claim 4 wherein said tumor of the central nervous system is selected from the group consisting of neuroblastoma, retinoblastoma, glioblastoma and oligodendroglioma.

13. (Amended) A method for treatment of neoplastic diseases in a human in need of such treatment, which comprises administering to said human an effective amount of an arsenic compound, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of at least one other therapeutic agent.

14. (Amended) The method of claim 13 in which said other therapeutic agent is a chemotherapeutic agent or radiotherapeutic agent.

15. (Amended) The method of claims 1, 2, 3, or 13 in which said administration is made parenterally, topically, dermally, directly into the tumor or orally.

16. (Amended) The method of claim 13 in which said other therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26 (vumon), BCNU, all-trans retinoic acid, procarbazine, cytokines, and therapeutic vaccines.

17. (Amended) The method of claim 1, 2, 3 or 13 in which said administration is made via an implantation device.

18. (Amended) A method of treatment of hematopoietic disorders in a human in need of such treatment, which comprises administering one or more arsenic compounds to said human, wherein said hematopoietic disorder is selected from the group consisting of acute lymphocytic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, myeloid metaplasia, myeloid dysplastic syndrome, multiple myeloma and plasmacytoma.

Please add the following claims:

21. (New) The method of claim 1, wherein arsenic trioxide is administered intravenously in a total daily dose of from 0.5 mg to 150 mg.

22. (New) The method of claim 2, wherein arsenic trioxide is administered intravenously in a total daily dose of from 0.5 mg to 150 mg.

23. (New) The method of claim 3, wherein arsenic trioxide is administered intravenously in a total daily dose of from 0.5 mg to 150 mg.

24. (New) The method of claim 1, 2, or 3, wherein the arsenic compound is an arsenic halide.

25. (New) The method of claim 1, 2, or 3, wherein the arsenic compound is an arsenic sulfide.

26. (New) The method of claim 1, 2, or 3, wherein the arsenic compound is an organic compound.

27. (New) The method of claim 1, 2, or 3, wherein the arsenic compound is administered as a prodrug.

28. (New) The method of claim 1, 2, or 3, wherein the arsenic compound is administered orally.

29. (New) The method of claim 1, 2, or 3, wherein the arsenic compound is administered as a pill or tablet.